



**INVEST LIKE A PRO, WITH THE PROS!**



Good morning!



Here's your chance to listen to the [podcast version](#) of our interview with *Traci Costa*, founder and CEO of *Peekaboo Beans (CSE:BEAN)*.

She details the company's strategy shift to an omni-channel model, its partnership with Shopify, and Peekaboo's move deeper into social media.

---

# Morning Need to Know

Getting you ready for your investing day

December 20, 2018

Written & compiled by Mark Bunting, Publisher,  
Capital Ideas Media

---



---

## CANADIAN ANALYSTS' CALLS

---

### INITIATIONS

#### Chartwell Retirement Residences (TSX:CSH.UN)

RBC upgrades to "outperform" and keeps the price target at \$16.50 (Canadian), implying 22% upside, calling the company a *"best-in-class owner/manager/developer with a strong brand."*

---



---

## U.S. ANALYSTS' CALLS

---

### INITIATIONS

## **eHealth (NASDAQ:EHTH)**

RBC starts coverage with an "outperform" and a target of \$57 (U.S.), indicating a 65% gain.

*RBC says "eHealth provides an online marketplace for the comparison and enrolment in health insurance plans, with a focus on the rapidly growing Medicare Advantage market."*

**G1 Therapeutics (NASDAQ:GTHX)** is started at "strong buy" by Raymond James with a target of \$61. The stock fell Wednesday on some disappointing clinical trial results.

**Bluebird Bio** started at "strong buy" at Raymond James with a target of \$165.

\*\*

**PPG Industries (NYSE:PPG)** RBC upgrades to "outperform" and boosts the target to \$121 from \$105, suggesting a 27% gain.

**Eli Lilly (NYSE:LLY)** J.P. Morgan lifts the target to \$128 from \$123 saying the company is growing faster than its peers.

---

## **STOCKS THAT MAY MOVE**

---

**Blackberry (TSX:BB;NASDAQ:BBRY)** swung to a quarterly net profit of \$59 million versus a loss last year of \$275 million (one-time charge related to Nokia dispute). Ex-items, profit was

5 cents a share, ahead of the 2 cent estimate.

**Tilray (NASDAQ:TLRY)** followed its partnership announcement with Novartis with a \$100 million joint venture deal with AB Imbev to develop cannabis-infused non-alcoholic drinks.

**Granite REIT (TSX:GRT.UN;NYSE:GRP.UN)** has arranged a \$185 million four year senior unsecured non-revolving term facility.

**Aphria (TSX:APHA;NYSE:APHA)** has signed a letter of intent with the Argentinian state-owned Cannabis Avatãra Sociedad del Estado to cultivate cannabis.

**Altria (NYSE:MO)** is confirming its taking a \$12.8 billion, 35% stake in Juul, the company that makes the hugely popular and controversial Juul e-cigarettes.

*With files from The Globe and Mail, Reuters and Bloomberg News.*

---

## MARKETS

---

**TSX and U.S. equity indices** are pointing to a mixed opening after the sharp sell-off yesterday when the U.S. Federal Reserve was not as dovish in its commentary as the market would have liked.

Global stocks are on pace for their fifth loss in a row and Asian indices fell overnight with Japan's Nikkei dropping 2.8%.

---

# CURRENCIES

---

The Canadian dollar is modestly higher at \$0.7424 (U.S).

---

# COMMODITIES

---

West Texas Intermediate is down nearly 3% at \$46.74 a barrel.

Gold is up slightly at \$1,260.00 an ounce.

---

## Daily Update

---

- ▶ Market Cap: \$897 million
- ▶ Dividend Yield: 1.1%
- ▶ Five Year Return: 400%
- ▶ One Year return: 18%
- ▶ Projected One Year Return: 31%

That's the Tale of the Tape for the cover story idea in the [\*new Capital Ideas Digest\*](#).

It's a company well positioned to continue to capitalize on e-commerce and a growing relationship with Amazon.com.

---



Also, be sure to see a [new interview](#) with **Adam Cegielski**, the founder and CEO of **Eyecarrot Innovations (TSXV:EYC)**, which is disrupting the vision care market with new technology, and has big plans to ramp up revenue in 2019.

Enjoy your day!

---

Access, insight and ideas.

**Mark Bunting**  
Publisher,  
**Capital Ideas Media**





---

The information and recommendations made available here (“Information”) by CIR and/or all affiliates is for informational purposes only and not to be used or construed as an offer to sell or a solicitation of an offer to buy any services or securities. You further agree that neither Capital Ideas Research will be liable for any losses or liabilities that may be occasioned as a result of the information or commentary provided in the letter. By accessing the site and reading this note, you accept and agree to be bound by and comply with the terms and conditions set out herein. If you do not accept and agree to the terms, you should not use this site or accept this email.

CIR is not registered as an adviser under the securities legislation of any jurisdiction of Canada and provides the Information pursuant to an exemption from the registration requirements that is available in respect of generic advice. The recommendations contained on the site and in this email are not tailored to the needs of particular persons and may not be appropriate for you depending on your financial position or investment goals or needs. You should apply your own judgment in making any use of the Information, especially as the basis for any investment decision. Prior to making any investment decision, we recommend that you seek outside advice from a qualified and registered investment advisor.

In no event will CIR be responsible or liable to you or any other party for any damages of any kind arising out of or relating to the use of, misuse of or inability to use this site and email. The Information is directed only at persons resident in Canada. Nothing in this site shall constitute an offer or solicitation to anyone in the United States of America or any jurisdiction where such offer or solicitation is not authorized or to any person to whom it is unlawful to make such a solicitation. If you choose to access this site or email from outside of Canada, you acknowledge that the Information is intended for use by persons resident in Canada only.

This is not an investment advisory, and should not be used to make investment decisions. Information in CIR is often opinionated and should be considered for information purposes only. No stock exchange anywhere has approved or disapproved of the information contained herein. There is no express or implied solicitation to buy or sell securities. The writers and editors of CIR may have positions in the stocks discussed above and may trade in the stocks mentioned. Don’t consider buying or selling any stock without conducting your own due diligence.



You are receiving this email because you are part of our investment network.

[Add us to your address book](#)

[unsubscribe from this list](#) [update subscription preferences](#)

---

This email was sent to <<Email Address>>

[why did I get this?](#) [unsubscribe from this list](#) [update subscription preferences](#)

Capital Ideas Research · HSBC Bank Place · 10250 101 Street Suite 1803 · Edmonton, Alberta T5J 3P4 · Canada